Simmonds SJ, Cuijpers I, Heymans S, Jones EAV (2020) Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding
Elisabetta Bugianesi serves as a consultant for Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Pfizer, Bristol-Myers Squibb, and MSD
One important caveat applies to the compounded version specifically: compounded preparations do not carry FDA-approved labeling of their own, so the adverse reaction data comes from the approved products that share the active moiety
Availability of Other Generic GLP-1 Drugs While liraglutide is now available in a generic form, its important to note that not all GLP-1 medications have generics on the market
This means that while the association is clear and the mechanisms are well-hypothesized, definitive answers about causation, dose-response relationships, and optimal prevention remain areas of active investigation
Retatrutide is an investigational medicine studied for obesity and related metabolic conditions